[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644849":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":22,"responsibleParty":36,"collaborators":10,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":10,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"mCRPC Cohort",null,"Adult male patients with a recent diagnosis of mCRPC in PRECISION.",[13],{"name":14,"affiliation":14,"role":15},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[17,21],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":14,"role":18,"phone":10,"phoneExt":10,"email":10},[23],{"facility":5,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":10},"RECRUITING","East Hanover","New Jersey","07936","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-74.36487,40.8201,{"lat":34,"lon":33},{"type":37,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100644849","a-study-of-real-world-characteristics-treatment-patterns-and-clinical-outcomes-in-patients-with-metastatic-castration-resistant-prostate-cancer-100644849",false,"NCT07677254","A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer","Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Contemporary Patients With Metastatic Castration-Resistant Prostate Cancer in the PRECISION Data Platform","Inclusion criteria:\n\n* Diagnosis of mCRPC between 01 January 2021 and 31 December 2025.\n* Male sex at index, where index is the date of initial mCRPC diagnosis.\n* Age 18 years at index.\n\nExclusion criteria:\n\n• None","MALE","18 Years","115 Years",{"count":49,"type":50},17111,"ESTIMATED","OBSERVATIONAL","The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.",[54],"Prostatic Neoplasms, Castration-Resistant",[56,57,58],"Metastatic Castration-Resistant Prostate Cancer","Androgen Pathway Modulation-Resistant","APMR","2026-07-15",{"date":61,"type":62},"2026-07-16","ACTUAL",{"date":64,"type":62},"2026-06-30",{"date":66,"type":50},"2026-11-30",{"name":14,"class":6},1]